Πλοήγηση ανά Θέμα "Infliximab"
Αποτελέσματα 1-4 από 4
-
Drug Discontinuation in Studies Including a Switch From an Originator to a Biosimilar Monoclonal Antibody: A Systematic Literature Review
(2019)Purpose: In observational studies of patients switched from stable treatment with an originator monoclonal antibody (mAb) to a biosimilar, higher rates of biosimilar discontinuation versus those observed in blinded switching ... -
Infliximab therapy for patients with active and refractory spondyloarthropathies at the dose of 3 mg/kg: A 20-month open treatment
(2004)Background: Infliximab at the dose of 5 mg/kg per infusion has been shown effective for the treatment of active spondyloarthropathies. It is not clear if the 5 mg/kg is required in most patients. Objective: To evaluate the ... -
Miliary tuberculosis in a patient with rheumatoid arthritis following treatment with anti-TNF-α
(2008)Anti-TNF-α agents have been used for the treatment of several autoimmune diseases, including rheumatoid arthritis. Recently observations indicate that treatment with anti-TNF-α agents is associated with increased risk of ... -
Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis
(2016)Genetic biomarkers could be useful for orienting treatment of patients with rheumatoid arthritis (RA), but none has been convincingly validated yet. Putative biomarkers include 14 single nucleotide polymorphisms that have ...